These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34994624)

  • 1. Divergent
    Rehman M; Kim C; Reuss JE; Kiedrowski LA; Garg RJ; Liu SV
    JCO Precis Oncol; 2021 Nov; 5():939-942. PubMed ID: 34994624
    [No Abstract]   [Full Text] [Related]  

  • 2. Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.
    Minari R; Bordi P; La Monica S; Squadrilli A; Leonetti A; Bottarelli L; Azzoni C; Lagrasta CAM; Gnetti L; Campanini N; Petronini PG; Alfieri R; Tiseo M
    J Thorac Oncol; 2018 Jun; 13(6):e89-e91. PubMed ID: 29596911
    [No Abstract]   [Full Text] [Related]  

  • 3. Landscape of Acquired Resistance to Osimertinib in
    Piotrowska Z; Isozaki H; Lennerz JK; Gainor JF; Lennes IT; Zhu VW; Marcoux N; Banwait MK; Digumarthy SR; Su W; Yoda S; Riley AK; Nangia V; Lin JJ; Nagy RJ; Lanman RB; Dias-Santagata D; Mino-Kenudson M; Iafrate AJ; Heist RS; Shaw AT; Evans EK; Clifford C; Ou SI; Wolf B; Hata AN; Sequist LV
    Cancer Discov; 2018 Dec; 8(12):1529-1539. PubMed ID: 30257958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC.
    Yan Y; Jiang G; Ma W; Li T; Wang L
    Clin Lung Cancer; 2020 Nov; 21(6):562-567. PubMed ID: 32622727
    [No Abstract]   [Full Text] [Related]  

  • 5. Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.
    La Monica S; Minari R; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Galetti M; Digiacomo G; Riccardi F; Petronini PG; Tiseo M; Alfieri R
    Target Oncol; 2019 Oct; 14(5):619-626. PubMed ID: 31502118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC.
    Freydman J; Henshaw L; Patel JV; Smith CE; Everett PC
    Ann Pharmacother; 2022 Apr; 56(4):503-504. PubMed ID: 34344199
    [No Abstract]   [Full Text] [Related]  

  • 7. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in
    Le X; Puri S; Negrao MV; Nilsson MB; Robichaux J; Boyle T; Hicks JK; Lovinger KL; Roarty E; Rinsurongkawong W; Tang M; Sun H; Elamin Y; Lacerda LC; Lewis J; Roth JA; Swisher SG; Lee JJ; William WN; Glisson BS; Zhang J; Papadimitrakopoulou VA; Gray JE; Heymach JV
    Clin Cancer Res; 2018 Dec; 24(24):6195-6203. PubMed ID: 30228210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies.
    Solassol J; Vendrell JA; Senal R; Audran P; Leenhardt F; Quantin X
    Lung Cancer; 2019 Jul; 133():45-47. PubMed ID: 31200827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy.
    Jelinek MJ; Armstrong SA; Patel JD; Subramaniam DS
    Clin Lung Cancer; 2019 Nov; 20(6):e597-e600. PubMed ID: 31542322
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.
    Okuno T; Arakawa S; Yoshida T; Ohe Y
    Lung Cancer; 2020 May; 143():95-96. PubMed ID: 32209253
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to First-Line Osimertinib Treatment in Non-Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations.
    Ikari T; Sakakibara-Konishi J; Yamamoto G; Kitai H; Mizugaki H; Asahina H; Kikuchi E; Shinagawa N
    Clin Lung Cancer; 2019 Jul; 20(4):e531-e533. PubMed ID: 31164318
    [No Abstract]   [Full Text] [Related]  

  • 12. L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.
    Bersanelli M; Minari R; Bordi P; Gnetti L; Bozzetti C; Squadrilli A; Lagrasta CA; Bottarelli L; Osipova G; Capelletto E; Mor M; Tiseo M
    J Thorac Oncol; 2016 Oct; 11(10):e121-3. PubMed ID: 27257132
    [No Abstract]   [Full Text] [Related]  

  • 13. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Giustini NP; Pritchard CC; Kamat NV; Menon MP
    JCO Precis Oncol; 2024 Jul; 8():e2300215. PubMed ID: 38991179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib.
    Fang W; Gan J; Huang Y; Zhou H; Zhang L
    J Thorac Oncol; 2019 Dec; 14(12):e274-e275. PubMed ID: 31757379
    [No Abstract]   [Full Text] [Related]  

  • 16. PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC.
    Vokes NI; Le X; Yap TA
    Clin Cancer Res; 2024 Sep; 30(18):3968-3970. PubMed ID: 39018064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC.
    Chen K; Zhou F; Shen W; Jiang T; Wu X; Tong X; Shao YW; Qin S; Zhou C
    J Thorac Oncol; 2017 Jun; 12(6):e65-e68. PubMed ID: 28093244
    [No Abstract]   [Full Text] [Related]  

  • 18. Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib.
    Makimoto G; Ohashi K; Senoo S; Hotta K; Maeda Y; Kiura K
    Intern Med; 2019 Jun; 58(11):1625-1627. PubMed ID: 30713295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osimertinib in Stage III
    Leighl NB
    N Engl J Med; 2024 Aug; 391(7):652-654. PubMed ID: 39141858
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis.
    Yoshida H; Ooi M; Kim YH
    J Thorac Oncol; 2018 Nov; 13(11):e219-e220. PubMed ID: 30368410
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.